Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

MedImmune and 4D Molecular Therapeutics to collaborate on AAV gene therapy

MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease.

AstraZeneca and Skoltech signed a memorandum on HR development cooperation

AstraZeneca and Skolkovo Institute of Science and Technology announced the signing of a memorandum of intent for improving the professional competencies in the pharmaceutical industry.

AstraZeneca resumes sales of Nexium in Russia

AstraZeneca, a biopharmaceutical company, announced that it registered new maximum ex-work prices in Russia for the tablets of Nexium (esomeprazole) included in the List of Vital and Essential Drugs (VED List).

AstraZeneca cut prices for socially important drugs in Russia by 12-92%

fas russia
The maximum ex-works prices for 11 trade names (8 INNs) of vital and essential drugs have been reduced within a short period of time. This price reduction ranged from 12 to 92 percent.

Emulate and AstraZeneca will jointly develop Organs-on-Chips technology

Emulate Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED.

AstraZeneca will develop novel stem cell-based therapies with SWIBCo

Procella Therapeutics and Smartwise entered the strategic research collaboration and commercialization agreement with AstraZeneca to develop novel stem cell-based therapies for heart failure and novel...

AstraZeneca will invest $90 million in India during the next five years

Leading global science-led biopharmaceutical company AstraZeneca announced its decision of further investing $90 million over the next 5 years in India.

AstraZeneca and SKOLKOVO launched Startup Challenge 2018 acceleration program

AstraZeneca and SKOLKOVO Foundation announced the launch of a joint acceleration program for projects in the area of oncology, cardiovascular, metabolic, kidney, respiratory, and autoimmune diseases.

Compugen signs an agreement with biologics R&D arm of AstraZeneca

Compugen Ltd., a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced it entered into an exclusive license agreement with MedImmune.

AstraZeneca’s hyperkalaemia drug is approved in the EU

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma for the treatment of adults with hyperkalaemia.

EMA accepted the submission for AstraZeneca’s diabetes drug

AstraZeneca announced that the European Medicines Agency has accepted the Marketing Authorisation Variation for Forxiga (dapagliflozin) for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).

Viela Bio spins out from AstraZeneca as an independent biotech company

Viela Bio announced that it has incorporated as an independent inflammation- and autoimmunity-focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca.

Pelago Bioscience started a new research collaboration with AstraZeneca

Pelago Bioscience AB has entered into a new strategic research collaboration and license agreement with AstraZeneca. In the last two years, the companies have collaborated on numerous Cellular Thermal...

Ionis Pharmaceuticals licenses a new renal drug to AstraZeneca

drug development
Ionis Pharmaceuticals, Inc. announced that it has licensed AZD2373 to the global, science-led biopharmaceutical company AstraZeneca. AstraZeneca will be responsible for developing and commercializing the drug.

AstraZeneca and IIDF sign a memorandum of collaboration

AstraZeneca, an international biopharmaceutical company, and the Internet Initiatives Development Fund (IIDF) signed a Memorandum of Intent to collaborate in the area of digital solutions for the pharmaceutical industry

GlobalData expects that Merck will set to lead licensing deals in 2018

Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData